Melatonin does not reduce mortality in adult hospitalized patients with COVID-19: a multicenter retrospective observational study

Marina Sánchez-Rico; Pedro de la Muela; Juan J Herrera-Morueco; Pierre A Geoffroy; Frédéric Limosin; Nicolas Hoertel; AP-HP/Université de Paris/INSERM COVID-19 Research Collaboration/AP-HP COVID CDR Initiative/Entrepôt de Données de Santé AP-HP Consortium

doi:10.1093/jtm/taab195

Melatonin does not reduce mortality in adult hospitalized patients with COVID-19: a multicenter retrospective observational study

J Travel Med. 2022 May 31;29(3):taab195. doi: 10.1093/jtm/taab195.

Authors

Affiliations

¹ AP-HP Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France.
² Campus de Somosaguas, Universidad Complutense de Madrid, Pozuelo de Alarcón, Spain.
³ Département de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hopital Bichat - Claude Bernard, F-75018 Paris, France.
⁴ GHU Paris - Psychiatry & Neurosciences, 1 rue Cabanis, 75014 Paris, France.
⁵ NeuroDiderot, Inserm, FHU I2-D2, Université de Paris, F-75019 Paris, France.
⁶ INSERM U1266, Paris, France.
⁷ Université de Paris, Paris, France.

Abstract

In this multicenter retrospective observational study involving 58 562 adult patients hospitalized for COVID-19, melatonin use (N = 272) at a mean daily dose of 2.6 mg was not associated with reduced mortality.

Keywords: COVID-19; SARS-CoV-2; death; efficacy; melatonin; mortality; treatment.

Publication types

Multicenter Study
Observational Study

MeSH terms

Adult
COVID-19*
Hospitalization
Humans
Melatonin* / therapeutic use
Retrospective Studies
SARS-CoV-2

Substances

Melatonin